Osteoporosis and fragility fractures in patients with acromegaly: A two-center cross-sectional study

Table 1 Patients demographic and clinical characteristics, n (%)

	Total (n = 124)
Male	67 (52)
Female	57 (48)
Age years, SD	44 (12)
Time from diagnosis years, SD	12 (8.8)
BMI at diagnosis, kg/m2, SD	27 (4.1)
Controlled disease	73 (58)
Active disease	51 (41)
Hypogonadism	12 (9.6)
Diabetes mellitus type 2	29 (23)
Adrenal insufficiency	21 (16)
Fragility fractures	27 (21)
Vertebral fractures	4 (3)
Non-vertebral	23 (18)

BMI: Body mass index.

Table 2 Bivariate analysis concerning the diagnosis of osteoporosis

Variable	Osteoporosis (n = 27)	No osteoporosis (n = 97)	P value
Age (years), mean ± SD	56 ± 14.6	53 ± 17.4	0.3670
Time of evolution (years), mean ± SD	11 ± 8.2	13 ± 11.9	0.4986
Body mass index (kg/m2), mean ± SD	27 ± 4	29 ± 5.1	0.0767
IGF-1 (mean, IC)	413 (173 to 1977)	624 (212 to 1140)	0.5186
Lanreotide or octreotide, n (%)	12 (46)	14 (15)	0.035a

^aP < 0.05.

Table 3 Bivariate analysis concerning the diagnosis of fragility fractures

Variable	Fracture (n = 27)	No fracture (n = 97)	P value
Age (years), mean ± SD	56 ± 18.3	55 ± 14.4	0.7519
Time of evolution (years), mean ± SD	12 ± 10.8	11.9 ± 8.7	0.9951
Body mass index (kg/m2), mean ± SD	26 ± 4.4	27 ± 4.4	0.5083
IGF-1 (mean, IC)	429 (224 to 1072)	454 (173 to 1977)	0.9241
Lanreotide or octreotide, n (%)	14 (52)	60 (62)	0.712

IGF-1: Insulin-like growth factor.